Detail akcie Integra Lifesci online

Business Summary: Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Integra Lifesciences Holdings Corp revenues decreased 1% to $1.54B. Net income decreased 62% to $67.7M. Revenues reflect Tissue Technologies segment decrease of 10% to $482.6M, United States segment decrease of 2% to $1.1B, Europe segment decrease of 3% to $165.2M, Rest of world segment decrease of 1% to $82.5M. Net income also reflects Tissue Technologies segment income decrease of 43% to $134M.